Diesel engines like the 3.0L Duramax require special maintenance, including the use of DEF, or Diesel Exhaust Fluid. Now, GM ...
GM recalls nearly 600,000 vehicles for L87 V8 engine failures after 1,000+ complaints. Multiple lawsuits now consolidated and the class action lawsuit is set to begin; plaintiffs claim GM's repair ...
It looks like GM is working on modernising two-stroke engines by tackling their emissions problem. This could open a whole new chapter for internal combustion. It’s been a while since two-stroke ...
General Motors will be one of the few automakers to ditch support for Apple CarPlay and Android Auto. Apple CarPlay and Android Auto are screen-mirroring apps that let you interact with many of the ...
Artur is a copywriter and SEO specialist, as well as a small business owner. In his free time, he loves to play computer games and is glad that he was able to connect his professional career with his ...
GM has released a Service Update through the National Highway Traffic Safety Administration (NHTSA) for the 2020-2022 Chevy Bolt EV and Chevy Bolt EUV. Service Update N232421261 addresses a condition ...
During a fireside chat with Meta CEO Mark Zuckerberg at Meta’s LlamaCon conference on Tuesday, Microsoft CEO Satya Nadella said that 20% to 30% of code inside the company’s repositories was “written ...
As one of the world's biggest car companies, Chevrolet sells an enormous number of vehicles every year – 1,745,809 in the United States in 2024 alone. Currently offering 24 models, Chevrolet offers a ...
Artur is a copywriter and SEO specialist, as well as a small business owner. In his free time, he loves to play computer games and is glad that he was able to connect his professional career with his ...
Ropeginterferon alfa-2b-njft (P1101) achieved durable hematologic responses in ET patients with a manageable safety profile, outperforming anagrelide in the SURPASS-ET trial. P1101 showed a ...
With phase 3 trial win, PharmaEssentia plots label expansion for rare blood cancer treatment Besremi
PharmaEssentia is looking to expand the reach of its FDA-approved rare blood cancer treatment Besremi to another rare blood disorder after reviewing encouraging results from a phase 3 study. In the ...
Findings showed 42.9% of P1101-treated patients achieved durable responses at both 9 and 12 months compared with 6% in those treated with anagrelide (P =.0001). Topline data were announced from a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback